Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02810340 · ClinicalTrials.gov registry record · Phase 1
Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults
A Phase 1 study, sponsored by PATH.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02810340 is a Phase 1 study that has completed, run by PATH. The registered enrollment target is 60 participants.
The verdict
NCT02810340, a Phase 1 study, has completed, sponsored by PATH.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety of adjuvanted and non-adjuvanted formulations of MCV-5 vaccine. The secondary objective is to assess the immune response of adjuvanted and non-adjuvanted formulations of MCV-5 vaccine.
Interventions
- BIOLOGICAL Menactra®
- BIOLOGICAL Adjuvanted MCV-5
- BIOLOGICAL Non-Adjuvanted MCV-5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-08-01 |
| Est. Completion | 2017-10-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02810340
The ClinicalTrials.gov registry entry for NCT02810340 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PATH, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Menactra® is the first listed.
NCT02810340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02810340 about?
NCT02810340 is a clinical study titled "Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults". The primary objective of this study is to evaluate the safety of adjuvanted and non-adjuvanted formulations of MCV-5 vaccine. The secondary objective is to assess the immune response of adjuvanted and non-adjuvanted formulations of MCV-5 vaccine.
What is the current status of trial NCT02810340?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2016-08-01. Estimated completion is 2017-10-13.
What interventions are being tested in trial NCT02810340?
The interventions under investigation include: Menactra® (BIOLOGICAL), Adjuvanted MCV-5 (BIOLOGICAL), Non-Adjuvanted MCV-5 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02810340?
This trial is sponsored by PATH, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.